RSS-Feed abonnieren
DOI: 10.1055/s-0045-1802966
Outcome of Immunotherapy in Advanced Cervical Cancer after Progression to Platinum-Based Therapy in the Real World
Funding The authors declare that they did not receive funding from agencies in the public, private, or non-profit sectors to conduct the present study.
Abstract
Introduction Cervical cancer remains a global health concern, particularly in low- and middle-income countries. Immunotherapy has demonstrated meaningful improvements in the overall survival (OS) of patients with recurrent, persistent, or metastatic disease that progressed to platinum-containing chemotherapy. The present study aimed to evaluate real-world outcomes with the use of immunotherapy in this setting.
Materials and Methods The current retrospective observational study included patients with recurrent, persistent, or metastatic cervical cancer who were exposed to single-agent immunotherapy at Oncoclínicas&CO private healthcare oncology network from July 2017 to January 2024. We performed descriptive statistics and estimated the time until treatment discontinuation (TTD) and OS through the Kaplan-Meier method.
Results In total, 60 patients met the inclusion criteria: 33 (55%) received cemiplimab, 26 (43.3%), pembrolizumab, and only 1 (1.7%), nivolumab. Most received immunotherapy as the second-line treatment (85%) after chemotherapy plus bevacizumab (64%). After a median follow-up of 12 months, the median TTD was of 6.3 months (95% confidence interval [95%CI]: 4.7–9.6), and the median OS was of 10.7 months (95%CI: 9.1–not reached [NR]).
Conclusion The present real-world study demonstrated comparable outcomes of single-agent immunotherapy for advanced cervical cancer with those described in pivotal clinical trials. These findings support the reproducibility and efficacy of immunotherapy, highlighting its role as a valuable treatment option in platinum-resistant cervical cancer.
Authors' Contributions
GVG and RD: data analysis and interpretation, final approval of the manuscript, and manuscript writing; RDP and CLN: collection and assembly of data, data analysis and interpretation, and final approval of the manuscript; and ACM: conception and design, final approval of the manuscript, and manuscript writing.
Clinical Trials
None.
Ethics Committee Number
6.486.262
Publikationsverlauf
Eingereicht: 17. September 2024
Angenommen: 25. November 2024
Artikel online veröffentlicht:
07. März 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil
Giovanna Vieira Giannecchini, Rafael Duarte Paes, Christopher Lucas Negrete, Rodrigo Dienstmann, Andreia Cristina de Melo. Outcome of Immunotherapy in Advanced Cervical Cancer after Progression to Platinum-Based Therapy in the Real World. Brazilian Journal of Oncology 2025; 21: s00451802966.
DOI: 10.1055/s-0045-1802966
-
References
- 1 Hull R, Mbele M, Makhafola T. et al. Cervical cancer in low and middle-income countries. Oncol Lett 2020; 20 (03) 2058-2074
-
2 Santos M de O. Lima FC da S de, Martins LFL, Oliveira JFP, Almeida LM de, Cancela M de C. Estimated Cancer Incidence in Brazil, 2023–2025 [Internet]. INCA, Ministério da Saúde; 2023 [cited 2023 Dec 16]. Available from: https://rbc.inca.gov.br/index.php/revista/article/view/3700
- 3 Colombo N, Dubot C, Lorusso D. et al; KEYNOTE-826 Investigators. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med 2021; 385 (20) 1856-1867
- 4 Tewari KS, Monk BJ, Vergote I. et al; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Survival with Cemiplimab in Recurrent Cervical Cancer. N Engl J Med 2022; 386 (06) 544-555
- 5 Chung HC, Ros W, Delord JP. et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 2019; 37 (17) 1470-1478
- 6 Naumann RW, Hollebecque A, Meyer T. et al. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. J Clin Oncol 2019; 37 (31) 2825-2834
- 7 Sherer MV, Kotha NV, Williamson C, Mayadev J. Advances in immunotherapy for cervical cancer: recent developments and future directions. Int J Gynecol Cancer 2022; 32 (03) 281-287
- 8 Grau-Bejar JF, Garcia-Duran C, Garcia-Illescas D, Mirallas O, Oaknin A. Advances in immunotherapy for cervical cancer. Ther Adv Med Oncol 2023; 15 17588359231163836
- 9 Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Adv Ther 2018; 35 (11) 1763-1774
- 10 Saesen R, Van Hemelrijck M, Bogaerts J. et al. Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer. Eur J Cancer 2023; 186: 52-61
- 11 Harari S. Randomised controlled trials and real-life studies: two answers for one question. Eur Respir Rev 2018; 27 (149) 180080
-
12 National Comprehensive Cancer Network (NCCN) [Internet]. NCCN Clinical Practice Guidelines in Oncology - Cervical Cancer, Version 1.2024. [cited 2024 Jan 9]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf